Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Trial details
- Registry ID
- NCT05065216
- Drugs studied
- Recombinant human tissue kallikrein
TrialRedline tracks 2 clinical trials sponsored by DiaMedica Therapeutics Inc: 1 Phase 2 / 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)NCT05065216 | Recombinant human tissue kallikrein | Recruiting | 2026-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)NCT04123613 | DM199 | Completed | 2022-03-16Actual |
Names as written in the registry records.